Tamoxifen Drug Asset Due Diligence Report 2026

This Tamoxifen Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1

Highest phase

Registered trials

Result records

100

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Tamoxifen can convert its Small molecule drug profile and ER biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tamoxifen (query alias: tamoxifen)
Modality / target	Small molecule drug; ER; ERs modulators
Highest global status	Phase 1
Originator	Daré Bioscience, Inc.
Active developers	Daré Bioscience, Inc.

The MCP disease footprint includes Vaginal Diseases, Dyspareunia, Vulvovaginal atrophy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
No matched detailed trial record returned.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Modern associations of uterine carcinomas with prior exposure to tamoxifen (2144)

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adenosarcoma = 0.9 % ; Adenosarcoma = 1.9 %

Endometrial surveillance strategy for detection of tamoxifen-related uterine cancers (2235)

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Menopausal = 57 %

Abstract PD15-12: PD15-12 A pre-surgical window trial of oral tamoxifen versus transdermal 4-hydroxytamoxifen gel in women with estrogen receptor positive duct carcinoma in situ (DCIS)

Phase 2; n=107; evaluation: Negative. Reported fields: Ki67 labeling index (LI) = -1.3 % ; Ki67 labeling index (LI) = -3.7 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tamoxifen addresses Vaginal Diseases, Dyspareunia, Vulvovaginal atrophy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 100 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ER records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-30	Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform	Preclinical	Financial terms not disclosed
2026-05-12	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	Approved	US$70.0M upfront; US$335.0M milestones
2026-03-31	LG Chem to develop and commercialize Mochida Pharmaceutical's Dinagest against endometriosis in South Korea and Thailand	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Tamoxifen citrate gel with rapid permeability”. The milestone feed surfaced a patent-application signal described as “Application of tamoxifen in preparation of medicine for resisting novel coronavirus”. The milestone feed surfaced a patent-application signal described as “Tamoxifen citrate particles”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION